ARCT vs. EOLS, LBPH, ALXO, TNGX, IRON, PRAX, DNTH, ZNTL, PLRX, and PRTC Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Evolus (EOLS), Longboard Pharmaceuticals (LBPH), ALX Oncology (ALXO), Tango Therapeutics (TNGX), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Dianthus Therapeutics (DNTH), Zentalis Pharmaceuticals (ZNTL), Pliant Therapeutics (PLRX), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical preparations" industry.
Evolus (NASDAQ:EOLS ) and Arcturus Therapeutics (NASDAQ:ARCT ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
Arcturus Therapeutics received 86 more outperform votes than Evolus when rated by MarketBeat users. However, 71.94% of users gave Evolus an outperform vote while only 65.39% of users gave Arcturus Therapeutics an outperform vote.
Evolus has a net margin of -27.31% compared to Evolus' net margin of -81.59%. Arcturus Therapeutics' return on equity of 0.00% beat Evolus' return on equity.
Evolus has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
In the previous week, Evolus had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Evolus and 9 mentions for Arcturus Therapeutics. Evolus' average media sentiment score of 0.67 beat Arcturus Therapeutics' score of 0.47 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
90.7% of Evolus shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 5.4% of Evolus shares are held by insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Evolus currently has a consensus price target of $20.60, indicating a potential upside of 51.58%. Arcturus Therapeutics has a consensus price target of $64.86, indicating a potential upside of 117.79%. Given Evolus' higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Evolus.
Arcturus Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary Arcturus Therapeutics beats Evolus on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Arcturus Therapeutics Competitors List
Related Companies and Tools
